[[1. AN INDUSTRY BUILT AROUND A DIFFERENT PROBLEM]]
The modern supplement industry did not develop primarily to serve high-performance athletes. It developed in response to a public health problem: populations with inadequate nutrient intake and the associated risk of deficiency disease. The regulatory frameworks, the reference standards, and the commercial infrastructure that govern how supplements are formulated, labelled, and marketed all reflect that origin.
Recommended Daily Allowances, the primary reference standard against which most supplement dosing is benchmarked, were designed to define the minimum intake required to prevent clinical deficiency in a largely sedentary general population. They were not designed to define optimal intake for individuals under physiological stress, nor to account for the increased micronutrient demand created by consistent training. The RDA is a floor, not a target, and it was set for a different population than the one most supplements now claim to serve.
This is the foundational mismatch. The industry inherited a set of standards calibrated to one problem and applied them to a product category ostensibly addressing a different one. A supplement formulated to RDA thresholds and marketed to athletes is using the wrong benchmark for the stated application. This is not a deliberate failure. It is the predictable consequence of an industry built on a regulatory framework built before the athletic performance market existed.
<<Quality problems in the supplement industry are visible and widely discussed. The structural problems are not. And they affect every product, regardless of quality.>>
[[2. HOW REGULATORY STANDARDS SHAPE FORMULATION]]
Regulatory frameworks create the boundaries within which commercial formulation decisions are made. In the supplement industry, those boundaries are defined primarily by reference to RDAs and Nutrient Reference Values, which determine what constitutes a meaningful dose for labelling purposes and what claims can be made about a product’s nutritional contribution.
For a supplement manufacturer, formulating to RDA thresholds is commercially rational. It satisfies regulatory requirements, allows broad nutritional claims on packaging, and keeps input costs low by avoiding the higher doses that a trained individual would actually require. The formula meets the standard. The standard, however, was not designed for the customer.
The result is a category in which products routinely include the right ingredients at doses that are technically compliant but physiologically insufficient for athletic application. A multivitamin providing 100 percent of the RDA for magnesium appears comprehensive on the label. For a sedentary individual it may be adequate. For an athlete losing magnesium through daily training and elevated metabolic demand, it represents a fraction of what is functionally required.
An athlete selecting a multivitamin that provides 100 percent of the RDA for magnesium may reasonably assume their magnesium requirements have been addressed. In practice, an athlete losing magnesium through sweat and elevated metabolic turnover may require substantially more than the RDA to maintain optimal physiological function. The product appears complete against the benchmark while leaving the functional deficit largely unchanged. The label is accurate. The benchmark is the problem.
An athlete comparing two products on the basis of their percentage of RDA is using a measurement standard that does not reflect their actual requirements. Both products may score well against the benchmark while both fail to address the physiological gap the athlete is actually trying to close.
<<Formulating to the RDA produces products that look complete on a label and function inadequately in practice. The benchmark is the problem. A product that meets the standard for a sedentary population does not meet the functional requirements of a trained one.>>
[[3. THE BIOAVAILABILITY PROBLEM]]
The dose reported on a supplement label is not the dose the body receives. The relationship between what is listed and what is absorbed depends on the form in which the ingredient is delivered, and this distinction is rarely communicated clearly to the consumer. In the mineral category in particular, the gap between labelled dose and absorbed dose is often substantial.
Compound weight versus elemental weight
Minerals in supplement formulas are not delivered as pure elements. They are bound to carrier compounds that provide stability and allow processing into tablet or powder form. Magnesium oxide, magnesium citrate, and magnesium bisglycinate all deliver magnesium, but the elemental magnesium content as a proportion of total compound weight varies considerably between forms. A label reporting 500 mg of magnesium bisglycinate is reporting the weight of the compound, not the elemental magnesium it contains. Without disclosure of elemental content, the reported dose cannot be meaningfully compared between products using different mineral forms.
This distinction is further obscured by inconsistent label conventions. The same mineral may appear on different products in formats such as: Magnesium bisglycinate — 100 mg, which typically reports the weight of the compound rather than the elemental magnesium it contains; Magnesium (as bisglycinate) — 100 mg, which reports 100 mg of elemental magnesium with the source form disclosed in parentheses; or Magnesium bisglycinate providing 100 mg magnesium, which names the compound and explicitly states the elemental yield. Each format communicates a different quantity of delivered magnesium, and the distinction is rarely explained on the label. A consumer comparing the 100 mg figure across these three products is not comparing equivalent doses.
The practical scale of this difference is significant. Two products both displaying 200 mg of magnesium on the front label may represent entirely different physiological doses. A product listing Magnesium (as bisglycinate) — 200 mg is delivering 200 mg of elemental magnesium using the bisglycinate form. A product listing Magnesium bisglycinate — 200 mg is reporting the compound weight, which at approximately 14 to 15 percent elemental magnesium by molecular weight yields around 28 to 30 mg of elemental magnesium. The headline number is identical. The delivered dose differs by a factor of roughly seven. Without understanding which convention a label is using, the stated dose is not an interpretable figure.
Absorbed dose versus labelled dose
Beyond compound weight, different mineral forms are absorbed at substantially different rates. Oxide forms, which are among the cheapest to produce, have notably lower absorption rates than chelated forms such as bisglycinate or glycinate. Two products reporting the same elemental magnesium content can deliver meaningfully different absorbed quantities depending solely on the mineral form used. The consumer comparing labels by dose alone is not comparing physiological effect. They are comparing numbers that reflect different underlying realities.
The practical consequence
An athlete purchasing a magnesium supplement based on the stated dose and the price per serving may be systematically selecting the least effective option available. The product with the highest stated dose at the lowest price is most likely to use oxide forms, which deliver the lowest absorbed quantity per milligram of compound weight. The product that appears to offer the best value frequently provides the least physiological return. This relationship is not accidental. It is a direct consequence of how cost structures interact with label conventions that do not require disclosure of absorbed dose or mineral form quality.
<<The label dose is not the absorbed dose. The compound weight is not the elemental weight. Without understanding these distinctions, a supplement label cannot be accurately interpreted, and product comparisons based on stated doses alone are not meaningful.>>
[[4. PROPRIETARY BLENDS AND LABEL OPACITY]]
A proprietary blend is a formulation approach in which multiple ingredients are grouped under a single declared weight, with individual ingredient quantities undisclosed. The total weight of the blend is listed on the label, but the contribution of each ingredient within it is not. This practice is permitted under current regulatory frameworks in most markets and is widespread across the supplement industry.
The commercial rationale is understandable. A manufacturer that has invested in developing an effective formula has a legitimate interest in protecting it from direct replication. Disclosing exact ingredient quantities would allow any competitor to reproduce the formula precisely. The proprietary blend is the industry’s primary mechanism for protecting formulation investment.
The consequence for the consumer is that a product listing a proprietary blend of five ingredients at a total of three grams provides no information about whether any individual ingredient is present at a dose that produces a physiological effect. An ingredient with an established effective dose of one gram could be present at fifty milligrams, sufficient to appear on the label without contributing meaningfully to the formula’s function. The blend structure makes this unverifiable without access to the full formula, and the incentive structure it creates does not reliably favour correct dosing over cost-effective label construction.
<<A proprietary blend discloses ingredients but not doses. Without knowing the dose of each ingredient, it is not possible to assess whether any individual component is present in a quantity sufficient to produce a physiological effect. The label is informative about what is in the product. It is uninformative about whether any of it is working.>>
[[5. MARGIN-DRIVEN FORMULATION]]
Supplement manufacturing is a competitive, low-margin business at the commodity end of the market. The cost of goods per serving is a primary determinant of commercial viability, and ingredient selection and dosing are significant drivers of that cost. This creates a structural incentive to formulate to the minimum dose that allows a claim to be made, rather than the dose at which the ingredient produces a meaningful physiological effect.
Certain ingredients are expensive per effective dose. Creatine monohydrate at five grams per serving costs considerably more per serving than creatine at one gram. A product that includes creatine at one gram can list creatine on the label and position it in marketing material as a key ingredient. The consumer who does not know that the established effective dose is approximately five grams per day has no basis for identifying the shortfall. The ingredient is present. The dose is not.
This pattern applies across multiple ingredient categories. B vitamins included at doses below functional thresholds. Antioxidant compounds present at quantities insufficient to meaningfully support the pathways they are associated with. Minerals included at doses that satisfy label requirements without reflecting the amounts needed to address the deficiencies established in ENG-A001. In each case, the formula is not fraudulent. The ingredients are present. The doses simply do not reflect what the physiology requires.
The market mechanism that would correct this, informed consumers selecting products based on effective dosing, does not function effectively in a category where the information required to make that assessment is either absent from the label or presented in a format that makes comparison difficult. Proprietary blends, compound weight reporting, and the absence of absorbed dose disclosure collectively ensure that consumers don’t have the information needed to tell effective products from ineffective ones.
<<The compounds that produce the most visible marketing returns are not always the compounds that produce the most physiological value. Label architecture optimises for perception, not for effect.>>
[[6. WHY THE MARKET SUSTAINS THESE PRACTICES]]
The structural problems described above persist not because the industry lacks the technical knowledge to address them, but because the incentive structure does not reward addressing them. Understanding why requires considering how supplement purchasing decisions are actually made.
Most consumers lack the technical background to evaluate a supplement formula against the physiological requirements it is meant to address. They rely on marketing claims, brand recognition, peer recommendation, and price-per-serving comparisons as proxies for quality. None of these proxies reliably correlates with formulation efficacy. A heavily marketed product at a competitive price point, using recognisable ingredient names in a proprietary blend, can outperform a transparently formulated, correctly dosed product in commercial terms while delivering substantially less physiological value.
This is not a market failure in the technical sense. It is a market functioning exactly as markets function when buyer information is limited. In a low-information environment, marketing substitutes for product quality as the primary driver of purchasing decisions. The manufacturer who invests in formulation quality rather than marketing reach is competing at a disadvantage in a market where the consumer cannot distinguish between the two.
The result is a category-level equilibrium in which under-dosing, low-bioavailability mineral forms, and opaque label structures are not aberrations. They are rational responses to a market that does not adequately penalise them. The incentive to formulate well exists only where the consumer can identify and reward good formulation. In most of the supplement market, that capacity does not reliably exist.
A practical illustration of this dynamic: an athlete who has used a heavily marketed pre-workout product for several months may not be able to identify whether it has meaningfully contributed to their performance, because the variables involved in training performance are numerous and the product’s effect, if sub-effective, is invisible. The product continues to be purchased because there is no clear signal that it is not working. The market receives no corrective feedback.
<<A product can be technically compliant, scientifically credible, and physiologically ineffective simultaneously. Compliance and efficacy are independent variables.>>
[[7. WHAT A STRUCTURALLY HONEST FORMULA REQUIRES]]
Given the structural incentives described above, a formula designed to genuinely serve the athlete rather than the economics of the category requires deliberate choices that run counter to the dominant commercial logic.
Dosing to functional thresholds, not regulatory minimums
Ingredients must be present at doses that reflect established effective thresholds rather than RDA benchmarks or label-compliance minimums. This applies particularly to compounds where there is a meaningful gap between the dose required for physiological effect and the dose that satisfies a regulatory claim. Where that gap exists, the formula must bridge it or the ingredient should not be included. An ingredient present below its effective dose adds label value without adding physiological value.
Mineral form selection for absorption, not cost
Mineral forms must be selected on the basis of bioavailability rather than cost per kilogram of raw material. Chelated forms, including bisglycinate and picolinate variants depending on the mineral, consistently demonstrate superior absorption compared to oxide and sulphate equivalents. The additional cost is not optional if the formula is intended to deliver the dose it claims at the absorbed level that produces physiological effect.
Full label transparency
Each ingredient must be disclosed at its individual dose. Proprietary blend structures that obscure individual ingredient quantities prevent the consumer from assessing whether effective doses are present. A formula with nothing to hide has no structural reason to use a proprietary blend. Transparency is not a marketing position. It is the minimum condition for an honest label.
Elemental content disclosure
Where minerals are included, labels should report elemental content rather than compound weight alone. Reporting 500 mg of magnesium bisglycinate without disclosing the elemental magnesium content allows the consumer to compare the compound weight against a product using a different mineral form, producing a comparison that does not reflect equivalent physiological doses. Elemental content disclosure allows meaningful comparison between products using different mineral forms.
Formulation calibrated to the actual user
Dosing decisions must reflect the physiological profile of the intended user. A formula marketed to trained individuals must be designed around the increased micronutrient demands, sweat losses, and recovery requirements of that population, not around the minimum intake thresholds established for the general population. The intended user is the benchmark. The RDA is not.
[[8. SYSTEM IMPLICATIONS]]
The structural problems described in this article are not peripheral issues. They determine whether a supplement formula does what it claims to do. A product that appears complete on its label, uses recognised ingredient names, and is priced competitively may deliver none of the physiological value its marketing implies, and the consumer has limited means of detecting this without understanding the mechanisms described above.
Reading a supplement label accurately requires knowing that the stated dose may not reflect the absorbed dose, that compound weight is not elemental weight, that an ingredient listed in a proprietary blend may be present at a fraction of its effective dose, and that RDA-aligned dosing was designed to prevent deficiency in a population that does not train.
This is not a framework for scepticism about supplementation as a category. The physiology established in the preceding articles is real, the deficiencies are real, and the performance implications of addressing them are real. The argument is more specific than that. It is that the supplement market, as currently structured, does not reliably produce formulas that address these problems effectively, and that the consumer cannot identify which products do without the analytical tools to interpret what a label is actually communicating.
Understanding the structural incentives that shape supplement formulation is a prerequisite for evaluating any formula honestly. A product that meets these criteria is not simply better marketed than one that does not. It is a fundamentally different category of thing, even if the label structure and the ingredient names look superficially similar.
<<The structural problems described in this article define the dominant operating model of the supplement industry. Understanding them is the prerequisite for evaluating any product accurately.>>